Beginning around 2017, the field of gene therapy transitioned from a state of experimental promise to the delivery of tangible, approved clinical treatments for a variety of inherited and acquired diseases. This period marked a pivotal shift in modern medicine, as researchers successfully demonstrated the ability to address the root causes of complex conditions by modifying the underlying genetic instructions within a patient's cells.

The therapeutic approach functions by altering, replacing, or adding genetic material to correct functional deficiencies or introduce new capabilities to the body. This methodology has unlocked unprecedented possibilities for treating disorders that were previously considered untreatable, offering hope to patients with limited medical alternatives. The rapid advancement of these techniques has necessitated a robust framework for safety and ethical oversight to ensure that these powerful interventions are applied responsibly and effectively.

Key developments during this transformative era include:

• The successful transition of genetic interventions from laboratory research to standardised clinical practice.
• The development of precise methods to modify genetic material for therapeutic benefit.
• The expansion of treatment options for previously incurable inherited and acquired conditions.
• The establishment of rigorous regulatory standards to manage the safety and ethical implications of gene editing.

As the technology continues to evolve, the focus remains on refining the delivery mechanisms and long-term efficacy of these treatments. The integration of gene therapy into mainstream healthcare represents a significant milestone in biotechnology, fundamentally changing the prognosis for many individuals living with chronic or life-limiting genetic conditions.